Polycythemia vera: A comprehensive review and clinical recommendations

Mayo Clinic Proceedings

Volumn 78, Issue 2, 2003, Pages 174-194

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANDROGEN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BUSULFAN; CHLORAMBUCIL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ERYTHROPOIETIN; HYDROXYUREA; MOLECULAR MARKER; PAROXETINE; PHOSPHORUS 32; PIPOBROMAN; RECOMBINANT ALPHA INTERFERON; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ABDOMINAL CRAMP; ALGORITHM; ALOPECIA; ANEMIA; ANOREXIA; AUTOIMMUNE DISEASE; BLEEDING; BONE MARROW APLASIA; CANCER RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CYTOPENIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG UTILIZATION; ERYTHROMELALGIA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEMATOCRIT; HEMOLYSIS; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERPIGMENTATION; LEG ULCER; LUNG FIBROSIS; MEDICAL INFORMATION; MOUTH ULCER; NAIL DISEASE; NAUSEA; NEUTROPENIA; PATHOPHYSIOLOGY; PHLEBOTOMY; POLYCYTHEMIA VERA; PRURITUS; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ULCER; SURVIVAL RATE; THROMBOSIS; TREATMENT CONTRAINDICATION; WEIGHT REDUCTION;

EID: 0037308442     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.2.174     Document Type: Review

References (340)

1. Vaquez LH. Sur une forme spéciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante. C R Soc Biol (Paris). 1892;44:384-388.
2. Osler W. Chronic cyanosis, with polycythaemia and enlarged spleen: a new clinical entity. Am J Med Sci. 1903;126:187-201.
3. Hippocrates. De humoribus. Chapter 1.
4. Avicenna. A Treatise on the "Canon of Medicine" of Avicenna (980-1037). London, England; 1930:276.
5. Von Haller A. Elementa Physiologiae Corporis Humani H. Laussane, Switzerland; 1757:34.
6. Wood GB. Treatise on the Practice of Medicine H. 1855:248.
7. Cuffer, Sollier P. Rev Med. 1889;9:825.
8. Turk W. Beitrage zur kenntnis des symptomenbildes polyzythamie mit milztumor und zyanose. Wien Med Wochenschr. 1904;17:153-160, 189-193.
9. Low J, Popper H. Wien Med Wochenschr. 1910;21:357.
10. Lesourd L, Pagniez P. C R Soc Biol. 1910;68:746.
11. Hirsch R. Generalized osteosclerosis with chronic polycythemia vera. Arch Pathol. 1935;19:91-97.
12. Rosenthal N, Bassen FA. Course of polycythemia. Arch Intern Med. 1938;62:903-917.
13. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
14. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A. 1967; 58:1468-1471.
15. Barr RD, Fialkow PJ. Clonal origin of chronic myelocytic leukemia. N Engl J Med. 1973;289:307-309.
16. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913-916.
17. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125-130.
18. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells. J Clin Invest. 1978;62:815-823.
19. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
20. Martin PJ, Najfeld V, Hansen JA, Penfold GK, Jacobson RJ, Fialkow PJ. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature. 1980;287:49-50.
21. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916-919.
22. Osler W. Erythremia (polycythemia with cyanosis, Maladie de Vaquez). Lancet. 1908;1:143-146.
23. Pack TT, Craver LF. Radiation therapy of polycythemia vera. Am J Med Sci. 1930;180:609-617.
24. Lawrence JH. Nuclear physics and therapy: preliminary report on a new method for the treatment of leukemia and polycythemia vera. Radiology. 1940;35:51-60.
25. Gardner FH. Early approaches in the treatment of polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, Pa: WB Saunders Co; 1995:147-153.
26. Wasserman LR. The management of polycythaemia vera. Br J Haematol. 1971;21:371-376.
27. Wasserman LR. The treatment of polycythemia: a panel discussion. Blood. 1968;32:483-487.
28. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. J Natl Cancer Inst. 1960;25:85.
29. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62:689-692.
30. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
31. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
32. Briere J, Kiladjian JJ, Peynaud-Debayle E. Megakaryocytes and platelets in myeloproliferative disorders. Baillieres Clin Haematol. 1997;10:65-88.
33. Tefferi A. Thrombocytosis and essential thrombocythemia. In: Michelson AD, ed. Platelets. Amsterdam, the Netherlands: Academic Press; 2002:667-679.
34. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121-131.
35. Silverstein MN, Lanier AP. Polycythemia vera, 1935-1969: an epidemiologic survey in Rochester, Minnesota. Mayo Clin Proc. 1971;46:751-753.
36. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ III. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994;47:89-93.
37. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 1992;48:20-26.
38. Ridell B, Carneskog J, Wedel H, et al. Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur J Haematol. 2000;65:267-271.
39. Modan B. An epidemiological study of polycythemia vera. Blood. 1965;26:657-667.
40. Prochazka AV, Markowe HL. The epidemiology of polycythaemia rubra vera in England and Wales 1968-1982. Br J Cancer. 1986;53:59-64.
41. Heudes D, Carli PM, Bailly F, Milan C, Mugneret F, Petrella T. Myeloproliferative disorders in the department of Cote d'Or between 1980 and 1986. Nouv Rev Fr Hematol. 1989;31:375-378.
42. Carli PM. Epidemiology of polycythemia vera in Cte d'Or (Burgundy). Nouv Rev Fr Hematol. 1994;36:147-149.
43. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15:173-189.
44. Reznikoff P, Foot NC, Bethea JM, Dubois FF. Racial and geographic origin by patients suffering from polycythemia vera and pathologic findings in blood vessels and bone marrow. Trans Assoc Am Physicians. 1934;49:273.
45. Damon A, Holub DA. Host factors in polycythemia vera. Ann Intern Med. 1958;49:43.
46. Modan B, Kallner H, Zemer D, Yoran C. A note on the increased risk of polycythemia vera in Jews. Blood. 1971;37:172-176.
47. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma. 1992;7:251-255.
48. Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther. 1998; 40:159-165.
49. Brubaker LH, Wasserman LR, Goldberg JD, et al. Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. Am J Hematol. 1984;16: 367-373.
50. Hemminki K, Jiang Y. Familial polycythemia vera: results from the Swedish Family-Cancer Database [letter]. Leukemia. 2001;15: 1313-1315.
51. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
52. Danish EH, Rasch CA, Harris JW. Polycythemia vera in childhood: case report and review of the literature. Am J Hematol. 1980;9:421-428.
53. Poggi V, Migliorati R, Fiore M, Amoroso R, Ghio R, Fiorillo A. Polycythemia vera: a new case report with onset in infancy. Haematologica. 1984;69:458-463.
54. Heilmann E, Klein CE, Beck JD. Primary polycythaemia in childhood and adolescence. Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110:935-941.
55. Modan B. The epidemiology of polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, Pa: WB Saunders Co; 1995:140-146.
56. Hayes RB, Blair A, Stewart PA, Herrick RF, Mahar H. Mortality of U.S. embalmers and funeral directors. Am J Ind Med. 1990; 18:641-652.
57. Hunter Fr. Chronic exposure to benzene (benzol), II: the clinical effects. J Indust Hygiene. 1939;21:331.
58. Kaplan SD. Update of a mortality study of workers in petroleum refineries. J Occup Med. 1986;28:514-516.
59. Caldwell GG, Kelley DB, Heath CW Jr, Zack M. Polycythemia vera among participants of a nuclear weapons test. JAMA. 1984; 252:662-664.
60. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors, part III: leukemia, lymphoma and multiple myeloma, 1950-1987 [published correction appears in Radiat Res. 1994;139:129]. Radiat Res. 1994;137(2, suppl):S68-S97.
61. Ash RC, Detrick RA, Zanjani ED. In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera: direct evidence of stem cell involvement. J Clin Invest. 1982; 69:1112-1118.
62. Raskind WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest. 1985;75:1388-1390.
63. Lucas GS, Padua RA, Masters GS, Oscier DG, Jacobs A. The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease. Br J Haematol. 1989;72:530-533.
64. Anger B, Janssen JW, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia. 1990; 4:258-261.
65. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunn HF. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1991; 88:6848-6852.
66. Asimakopoulos FA, Gilbert JG, Aldred MA, Pearson TC, Green AR. Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood. 1996;88:2690-2698.
67. Singer JW, Fialkow PJ, Adamson JW, et al. Polycythemia vera. Increased expression of normal committed granulocytic stem cells in vitro after exposure of marrow to tritiated thymidine. J Clin Invest. 1979;64:1320-1324.
68. Singer JW, Adamson JW, Ernst C, et al. Polycythemia vera: physical separation of normal and neoplastic committed granulocyte-macrophage progenitors. J Clin Invest. 1980;66:730-735.
69. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986; 233:212-214.
70. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1987;84:6558-6562.
71. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
72. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
73. Daley GQ, Van Etten RA, Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 1991;88:11335-11338.
74. Rege-Cambrin G, Mecucci C, Tricot G, et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet. 1987;25: 233-245.
75. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood. 1988;72:386-395.
76. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc. 1991;66;287-299.
77. Chen Z, Notohamiprodjo M, Guan XY, et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer. 1998;22:321-324.
78. Westwood NB, Gruszka-Westwood AM, Atkinson S, Pearson TC. Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica. 2001; 86:464-469.
79. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236.
80. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera [letter]. N Engl J Med. 1974;290:1382.
81. Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood. 1994;84:1982-1991.
82. Dobo I, Pineau D, Zatidecki M, Hunault M, Hermouet S. Endogenous erythroid and megakaryocytic colony formation in serumfree, cytokine-free collagen gels. J Hematother Stem Cell Res. 1999;8:601-607.
83. Dobo I, Mossuz P, Campos L, et al. Comparison of four serumfree, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Hematol J. 2001;2:396-403.
84. Zanjani ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro: dependence on erythropoietin. J Clin Invest. 1977;59:841-848.
85. Casadevall N, Vainchenker W, Lacombe C, et al. Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood. 1982; 59:447-451.
86. Montagna C, Massaro P, Morali F, Foa P, Maiolo AT, Eridani S. In vitro sensitivity of human erythroid progenitors to hemopoietic growth factors: studies on primary and secondary polycythemia. Haematologica. 1994;79:311-318.
87. Juvonen E, Partanen S, Ikkala E, Ruutu T. Megakaryocytic colony formation in polycythaemia vera and secondary erythrocytosis. Br J Haematol. 1988;69:441-444.
88. Juvonen E, Partanen S, Ruutu T. Colony formation by megakaryocytic progenitors in essential thrombocythaemia. Br J Haematol. 1987;66:161-164.
89. Battegay EJ, Thomssen C, Nissen C, Gudat F, Speck B. Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders. Eur J Haematol. 1989;42:321-326.
90. Florensa L, Besses C, Woessner S, et al. Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia. 1995;9:271-273.
91. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310-3321.
92. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994;83:99-112.
93. Dai CH, Krantz SB, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest. 1991;87:391-396.
94. Dai CH, Krantz SB, Dessypris EN, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera, II: hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80:891-899.
95. Dai CH, Krantz SB, Green WF, Gilbert HS. Polycythaemia vera, III: burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol. 1994;86:12-21.
96. Martin JM, Gandhi YK, Jackson WR, Dessypris EN. Hypersensitivity of polycythemia vera megakaryocytic progenitors to thrombopoietin [abstract]. Blood. 1996;88(pt 1, suppl 1):94a. Abstract 363.
97. Michl P, Spoettl G, Engelhardt D, Weber MM. Alterations of the insulin-like growth factor system in patients with polycythemia vera. Mol Cell Endocrinol. 2001;181:189-197.
98. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57:277-285.
99. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood. 1993;81:2223-2226.
100. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74:227-236.
101. Penta K, Sawyer ST. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem. 1995;270:31282-31287.
102. Kirito K, Uchida M, Takatoku M, et al. A novel function of Stat 1 and Stat3 proteins in erythropoietin-induced erythroid differentiation of a human leukemia cell line. Blood. 1998;92:462-471.
103. Watowich SS, Mikami A, Busche RA, Xie X, Pharr PN, Longmore GD. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of stat signals during red blood cell development. J Interferon Cytokine Res. 2000;20:1065-1070.
104. Zochodne B, Truong AH, Stetler K, et al. Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia. Oncogene. 2000;19:2296-2304.
105. Kirito K, Nakajima K, Watanabe T, et al. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood. 2002;99:102-110.
106. Bittorf T, Seiler J, Zhang Z, Jaster R, Brock J. SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem. 1999;380:1201-1209.
107. Okutani Y, Kitanaka A, Tanaka T, et al. Src directly tyrosinephosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene. 2001;20: 6643-6650.
108. Klingmuller U, Wu H, Hsiao JG, et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci USA. 1997;94:3016-3021.
109. Shan R, Price JO, Gaarde WA, Monia BP, Krantz SB, Zhao ZJ. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin [retracted in: Blood. 2001;97:843]. Blood. 1999;94:4067-4076.
110. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol. 1994;88:794-802.
111. Le Couedic JP, Mitjavila MT, Villeval JL, et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood. 1996;87:1502-1511.
112. Mittelman M, Gardyn J, Carmel M, Malovani H, Barak Y, Nir U. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leuk Res. 1996;20:459-466.
113. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993;90:4495-4499.
114. Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 1997;89:4628-4635.
115. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997;90:2057-2061.
116. Arcasoy MO, Karayal AF, Segal HM, Sinning JG, Forget BG. A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood. 2002;99:3066-3069.
117. Percy MJ, McMullin MF, Roques AW, et al. Erythrocytosis due to a mutation in the erythropoietin receptor gene. Br J Haematol. 1998;100:407-410.
118. Chiba S, Takahashi T, Takeshita K, et al. Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera. Blood. 1997;90:97-104.
119. Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood. 1995;86:877-882.
120. Wickrema A, Chen F, Namin F, et al. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999;27: 1124-1132.
121. Sui X, Krantz SB, Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood. 1997;90:651-657.
122. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29:694-702.
123. Dai C, Krantz SB. Increased expression of the INK4a/ARF locus in polycythemia vera. Blood. 2001;97:3424-3432.
124. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564-571.
125. Nishigaki K, Hanson C, Ohashi T, Thompson D, Muszynski K, Ruscetti S. Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins. J Virol. 2000;74:3037-3045.
126. Van Zant G, Shultz L. Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev). Exp Hematol. 1989;17:81-87.
127. Asimakopoulos FA, Hinshelwood S, Gilbert JG, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 1997;14:1215-1222.
128. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124.
129. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-538.
130. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-568.
131. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369: 571-574.
132. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995;92:3234-3238.
133. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost. 1997;77:808-814.
134. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85:2720-2730.
135. Stefanich E, Senn T, Widmer R, Fratino C, Keller GA, Fielder PJ. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood. 1997;89:4063-4070.
136. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood. 1997;89: 2782-2788.
137. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106:345-356.
138. Scheding S, Bergmann M, Shimosaka A, et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion. 2002;42:321-327.
139. Hou M, Andersson PO, Stockelberg D, Mellqvist UH, Ridell B, Wadenvik H. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol. 1998;101:420-424.
140. Kojima S, Matsuyama T, Kodera Y, Tahara T, Kato T. Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunosorbent assay. Br J Haematol. 1997;97:538-543.
141. Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol. 1997;99:281-284.
142. Wang JC, Chen C, Novetsky AD, Lichter SM, Ahmed F, Friedberg NM. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med. 1998;104:451-455.
143. Wang JC, Chen C, Lou LH, Mora M. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia. 1997;11:1827-1832.
144. Uppenkamp M, Makarova E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol. 1998;77:217-223.
145. Pitcher L, Taylor K, Nichol J, et al. Thrombopoietin measurement in thrombocytosis: dysregulation and lack of feedback inhibition in essential thrombocythaemia. Br J Haematol. 1997;99: 929-932.
146. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997;90:4031-4038.
147. Molitemo AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338:572-580.
148. Harrison CN, Gale RE, Pezella F, Mire-Sluis A, MacHin SJ, Linch DC. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol. 1999;107:139-147.
149. Yoon SY, Li CY, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur J Haematol. 2000;65:170-174.
150. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol. 2000;111:943-953.
151. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood. 1999;94:2555-2561.
152. Tefferi A, Yoon SY, Li CY. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood. 2000;96:771-772.
153. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood. 2002;99:4131-4137.
154. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 2000;95:2569-2576.
155. Bettinotti W, Olsen A, Stroncek D. The use of bioinformatics to identify the genomic structure of the gene that encodes neutrophil antigen NB1, CD177. Clin Immunol. 2002;102:138-144.
156. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand. 1962;172:513-523.
157. Pearson TC. Hemorheology in the erythrocytoses. Mt Sinai J Med. 2001;68:182-191.
158. Thomas DJ, du Boulay GH, Marshall J, et al. Cerebral blood flow in polycythaemia. Lancet. 1977;2:161-163.
159. Brown MM, Wade JP, Marshall J. Fundamental importance of arterial oxygen content in the regulation of cerebral blood flow in man. Brain. 1985;108(pt 1):81-93.
160. Milligan DW, Tooke JE, Davies JA. Effect of venesection on calf blood flow in polycythaemia. Br Med J (Clin Res Ed). 1982;284: 619-620.
161. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science. 1980;207:541-543.
162. McLacMin AD, McLachlin JA, Jory TA, Rawling EG. Venous stasis in the lower extremities. Ann Surg. 1960;152:678-685.
163. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, Pa: WB Saunders Co; 1995:166-194.
164. Cooper B, Schafer AI, Puchalsky D, Handin RI. Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. Blood. 1978;52:618-626.
165. Mehta P, Mehta J, Ross M, Ostrowski N, Player D. Decreased platelet aggregation but increased thromboxane A2 generation in polycythemia vera. Arch Intern Med. 1985;145:1225-1227.
166. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood. 1992;80: 1965-1971.
167. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261-4266.
168. Musolino C, Alonci A, Bellomo G, et al. Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematol. 2000;4:397-402.
169. Wieczorek I, MacGregor IR, Prescott RJ, Ludlam CA. The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera. Blood Coagul Fibrinolysis. 1992;3:823-826.
170. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol. 1996;52:14-20.
171. Posan E, Ujj G, Kiss A, Telek B, Rak K, Udvardy M. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res. 1998; 90:51-56.
172. Cancelas JA, Garcia-Avello A, Garcia-Frade LJ. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res. 1994;75:513-520.
173. Afshar-Kharghan V, Lopez JA, Gray LA, et al. Hemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia [abstract]. Blood. 2001;98(pt 1):471a. Abstract 1967.
174. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985; 102:466-471.
175. van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost. 1996;76:333-338.
176. van Genderen PI, Prins FJ, Michiels JJ, Schror K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999;104:438-441.
177. Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR. Abnormalities of platelet function in patients with polycythemia vera. Cancer Res. 1973;33:2683-2687.
178. Weinfeld A, Branehog I, Kutti J. Platelets in the myeloproliferative syndrome. Clin Haematol. 1975;4:373-392.
179. Ushikubi F, Ishibashi T, Narumiya S, Okuma M. Analysis of the defective signal transduction mechanism through the platelet thromboxane A2 receptor in a patient with polycythemia vera. Thromb Haemost. 1992;67:144-146.
180. Le Blanc K, Berg A, Palmblad J, Samuelsson J. Stimulus- specific defect in platelet aggregation in polycythemia vera. Eur J Haematol. 1994;53:145-149.
181. Castaldi PA, Berndt MC, Booth W, Gregory C, Bull H, Greaves M. Evidence for a platelet membrane defect in the myeloproliferative syndromes. Thromb Res. 1982;27:601-609.
182. Cortellazzo S,Colucci M,Barbui T, Dini E, Semeraro N. Reduced platelet factor X-activating activity: a possible contribution to bleeding complications in polycythaemia vera and essential thrombocythaemia. Haemostasis. 1981;10:37-50.
183. Keenan JP, Wharton J, Shepherd AJ, Bellingham AJ. Defective platelet lipid peroxidation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. Br J Haematol. 1977;35: 275-283.
184. Le Blanc K, Lindahl T, Rosendahl K, Samuelsson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thromb Res. 1998;91:287-295.
185. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood. 1984;64:981-985.
186. Fabris F, Casonato A, Grazia del Ben M, De Marco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol. 1986; 63:75-83.
187. Mohri H. Acquired von Willebrand disease in patients with polycythemia rubra vera. Am J Hematol. 1987;26:135-146.
188. Tatewaki W, Takahashi H, Shibata A. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders. Clin Lab Haematol. 1988;10:417-425.
189. van Geaderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol. 1996;93:962-965.
190. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997; 23:425-431.
191. Pearson TC. Apparent polycythaemia. Blood Rev. 1991;5:205-213.
192. Fairbanks VF, Tefferi A. Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to 'apparent polycythemia'. Eur J Haematol. 2000;65:285-296.
193. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med. 1997;102:14-20.
194. Fairbanks VF. Myeloproliferative disease: polycythemia vera: the packed cell volume and the curious logic of the red cell mass. Hematol. 2000;4:381-395.
195. Gaisböck F. Die Bedeutung der Blutdruckmessung fur die Praxis. Arch Clin Med (Leipzig). 1905;83.
196. Lawrence JH, Berlin NI. Relative polycythemia: the polycythemia of stress. Yale J Biol Med. 1952;24:498-505.
197. Fairbanks VF, Wiseman GA. Rationales and outcomes in 109 consecutive red cell mass (RCM) and plasma volume measurements: tobacco abuse is the commonest cause of elevated RCM: stress erythrocytosis not encountered. Blood. 1997;90(suppl 1, pt 2):25b. Abstract 2801.
198. Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med. 1978;298:6-10.
199. Vanuxem D, Guillot C, Fomaris E, Weiller PJ, Grimaud C. Secondary polycythaemia in chronic respiratory insufficiency. Thorax. 1977;32:317-321.
200. Tyndall MR, Teitel DF, Lutin WA, Clemons GK, Dallman PR. Serum erythropoietin levels in patients with congenital heart disease. J Pediatr. 1987;110:538-544.
201. Milledge JS, Cotes PM. Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol. 1985;59: 360-364.
202. DiMarco AT. Carbon monoxide poisoning presenting as polycythemia [letter]. N Engl J Med. 1988;319:874.
203. Hoffstein V, Herridge M, Mateika S, Redline S, Strohl KP. Hematocrit levels in sleep apnea. Chest. 1994;106:787-791.
204. Hudgson P, Pearce JM, Yeates WK. Renal artery stenosis with hypertension and high haematocrit. BMJ. 1967;1:18-21.
205. Moo-Penn WF, Schneider RG, Shih T, et al. Hemoglobin Ohio (beta 142 Ala replaced by): a new abnormal hemoglobin with high oxygen affinity and erythrocytosis. Blood. 1980;56:246-250.
206. Galacteros F, Rosa R, Prehu MO, Najean Y, Calvin MC. Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis [in French]. Nouv Rev Fr Hematol. 1984;26:69-74.
207. Matsuyama M, Yamazaki O, Horii K, et al. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. J Surg Oncol. 2000;75:197-202.
208. Ndububa DA, Ojo OS, Adetiloye VA, Rotimi O, Durosinmi MA, Uchegbu LO. The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients. Eur J Gastroenterol Hepatol. 1999;11:1401-1404.
209. Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood. 2002;99:3562-3565.
210. Skultety FM, Sorrell MF, Burklund CW. Hemangioblastoma of the cerebellum associated with erythrocytosis and an unusual blood supply. JNeurosurg. 1970;32:700-705.
211. Weinstein RS. Parathyroid carcinoma associated with polycythemia vera. Bone. 1991;12:237-239.
212. Suzuki M, Takamizawa S, Nomaguchi K, et al. Erythropoietin synthesis by turnout tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol. 2001;113:49-51.
213. Jermanovich NB. Polycystic kidney disease and polycythemia vera: occurrence in a patient receiving hemodialysis. Arch Intern Med. 1983;143:1822-1823.
214. Drenou B, Le Tulzo Y, Caulet-Maugendre S, et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv Rev Fr Hematol. 1995;37:197-199.
215. Bruneval P, Sassy C,Mayeux P,et al. Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis. Blood. 1993;81:1593-1597.
216. Kulkarni V, Ritchey K, Howard D, Dainiak N. Heterogeneity of erythropoietin-dependent erythrocytosis: case report in a child and synopsis of primary erythrocytosis syndromes. Br J Haematol. 1985;60:751-758.
217. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002; 28:57-62.
218. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86:15-22.
219. Spivak JL. Erythropoietin use and abuse: when physiology and pharmacology collide. Adv Exp Med Biol. 2001;502:207-224.
220. Dickerman RD, Pertusi R, Zachariah NY, Schaller F. Androgen-induced erythrocytosis. Am J Hematol. 1998;59:263-264.
221. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol. 2001;68:115-121.
222. Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol. 2001;38:1020.
223. Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int. 1983;23:731-737.
224. Glicklich D, Kapoian T, Mian H, Gilman J, Tellis V, Croizat H. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation. 1999;68:62-66.
225. Wedzicha JA, Cotes PM, Empey DW, Newland AC, Royston JP, Tam RC. Serum immunoreactive erythropoietin in hypoxic lung disease with and without polycythaemia. Clin Sci (Lond). 1985;69:413-422.
226. Whitcomb WH, Peschle C, Moore M, Nitschke R, Adamson JW. Congenital erythrocytosis: a new form associated with an erythropoietin-dependent mechanism. Br J Haematol 1980;44:17-24.
227. Hellmann A, Rotoli B, Cotes PM, Luzzatto L. Familial erythrocytosis with over-production of erythropoietin. Clin Lab Haematol. 1983;5:335-342.
228. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia. Blood. 1997; 89:2148-2154.
229. Vasserman NN, Karzakova LM, Tverskaya SM, et al. Localization of the gene responsible for familial benign polycythemia to chromosome 1 lq23. Hum Hered. 1999;49:129-132.
230. Richard S, Croisille L, Yvart J, et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood. 2002;99:3851-3853.
231. de la Chapelle A, Sistonen P, Lehvaslaiho H, Ikkala E, Juvonen E. Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet. 1993;341:82-84.
232. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature. 2000;405:635.
233. Brox AG, Mangel J, Hanley JA, St Louis G, Mongrain S, Gagnon RF. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation. 1998;66:1053-1058.
234. Berlin NI. Diagnosis and classification of the polycythemias Semin Hematol. 1975;12:339-351.
235. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9-13.
236. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol. 1998;11:695-720.
237. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 1997;23: 339-347.
238. Napier JA, Janowska-Wieczorek A. Erythropoietin measurements in the differential diagnosis of polycythaemia. Br J Haematol. 1981;48:393-401.
239. Birgegard G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol. 1992;81:603-606.
240. Messinezy M, Westwood NB, Woodcock SP, Strong RM, Pearson TC. Low serum erythropoietin - a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin Lab Haematol. 1995;17:217-220.
241. Cameskog J, Kutti J, Wadenvik H, Lundberg PA, Lindstedt G. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol. 1998;60:278-282.
242. Griesshammer M, Kubanek B, Beneke H, et al. Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. Leuk Lymphoma. 2000;36:533-538.
243. Andreasson B, Lindstedt G, Stockelberg D, Wadenvik H, Kutti J. The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia. Leuk Lymphoma. 2001;41:579-584.
244. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol. 2002;117:47-53.
245. Cotes PM, Dore CJ, Yin JA, et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med. 1986;315:283-287.
246. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica. 2001;86:368-374.
247. Lemoine F, Najman A, Baillou C, et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 1986;68:996-1002.
248. Zwicky C, Theiler L, Zbaren K, Ischi E, Tobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br J Haematol. 2002;117:598-604.
249. Lawrence JH, et al. The nature and treatment of polycythemia. Medicine. 1953;33:323-388.
250. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1222.
251. Natvig H, Vellar OD. Studies on hemoglobin values in Norway, 8: hemoglobin, hematocrit and MCHC values in adult men and women. Acta Med Scand. 1967;182:193-205.
252. National Center for Health Statistics, Devine B. Mean blood hematocrit of adults: United States 1960-1962. Vital Health Stat 11.1967;24:1-36.
253. Thompson L. In: Cato AE, ed. Clinical Drug Trials and Tribulations. New York, NY: Dekker; 1988:413.
254. Kiraly JF III, Feldmann JE, Wheby MS. Hazards of phlebotomy in polycythemic patients with cardiovascular disease. JAMA. 1976;236:2080-2081.
255. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132-143.
256. Leukemias and Hematosarcomas Group. Treatment by radiophosphorus versus busulfan in polycythemia vera: a randomized trial (E.O.R.T.C.'s). Recent Results Cancer Res. 1977;62:104-109.
257. Leukemia and Hematosarcoma Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981;44:75-80.
258. Zittoun R. Busulfan versus 32P in polycythaemia vera. Drugs Exp Clin Res. 1986;12:283-285.
259. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-447.
260. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 1986;23: 144-155.
261. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23:172-176.
262. Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Hemost. 1997;23:473-478.
263. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
264. Najean Y, Rain JD, French Polycythemia Study Group. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood. 1997;89:2319-2327.
265. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol. 1986;23: 167-171.
266. Najman A, Stachowiak J, Parlier Y, Gorin NC, Duhamel G. Pipobroman therapy of polycythemia vera. Blood. 1982;59:890-894.
267. Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol. 1984;17:329-334.
268. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34:17-23.
269. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. South Med J. 1987;80:323-327.
270. Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol. 1997;34:24-28.
271. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000;85:1011-1018.
272. Petti MC, Spadea A, Avvisati G, et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia. 1998;12:869-874.
273. Brusamolino E, Salvaneschi L, Canevari A, Bemasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol. 1984;2:558-561.
274. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol. 1985;61:657-666.
275. D'Emilio A, Battista R, Dini E. Treatment of primary proliferative polycythaemia by venesection and busulphan. Br J Haematol. 1987;65:121-122.
276. Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera [letter]. Lancet. 1988;2:403.
277. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988;318:1292-1294.
278. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol. 1997;34:40-50.
279. Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 1997;23:463-472.
280. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost. 1997;23:379-383.
281. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92: 69-76.
282. Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN. New drugs in essential thrombocythemia and polycythemia vera. Blood Rev. 1997;11:1-7.
283. Kreft A, Nolde C, Busche G, Buhr T, Kreipe H, Georgii A. Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur J Haematol. 2000;64:32-41.
284. Wade JP. Transport of oxygen to the brain in patients with elevated hematocrit values before and after venesection. Brain. 1983;106(pt 2):513-523.
285. Pearson TC,Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol. 1979;1:189-196.
286. Littler WA, Kay JM, Hasleton PS, Heath D. Busulphan lung. Thorax. 1969;24:639-655.
287. Rosenow EC III, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect. 1995;10:86-95.
288. Comhaire F, Van Hove W, Van Ganse W, Van der Straeten M. Busulphan and the lungs: absence of lung function disturbance in patients treated with busulphan. Scand J Respir Dis. 1972;53:265-273.
289. Stuart JJ, Crocker DL, Roberts HR. Treatment of busulfan-induced pancytopenia. Arch Intern Med. 1976;136:1181-1183.
290. Stevens MR. Hydroxyurea: an overview. J Biol Regul Homeost Agents. 1999;13:172-175.
291. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol. 1993;43:316-318.
292. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233-235.
293. Zoppi M, Zamponi A, Pagni E, Buoncristiano U. A way to understand erythromelalgia. J Auton Nerv Syst. 1985;13:85-89.
294. Davis MD, O'Fallon WM, Rogers RS III, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000; 136:330-336.
295. Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997;242:191-197.
296. Brown GE, Giffin HZ. Peripheral arterial disease in polycythemia vera. Arch Intern Med. 1930;46:705-717.
297. Babb RR, Alarcon-Segovia D, Fairbairn IF. Erythermalgia: review of 51 cases. Circulation. 1964;29:136-141.
298. Michiels JJ, ten Kate FW, Vuzevski VD, Abels J. Histopathology of erythromelalgia in thrombocythaemia. Histopathology. 1984;8: 669-678.
299. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost. 1995;73: 210-214.
300. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol. 2001;115: 619-621.
301. Fjellner B, Hagermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol. 1979;59:505-512.
302. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. Blood. 1966;28:795-806.
303. Steinman HK, Kobza-Black A, Lotti TM, Brunetti L, Panconesi E, Greaves MW. Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. Br J Dermatol. 1987;116: 329-333.
304. Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol. 1987;116:21-29.
305. Buchanan JG, Ameratunga RV, Hawkins RC. Polycythemia vera and water-induced pruritus: evidence against mast cell involvement. Pathology. 1994;26:43-45.
306. Easton P, Galbraith PR. Cimetidine treatment of pruritus in polycythemia vera [letter]. N Engl J Med. 1978;299:1134.
307. Weick JK, Donovan PB, Najean Y, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med. 1982;142:241-242.
308. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus [letter]. Blood. 2002;99:2627.
309. Salem HH, Van der Weyden MB, Young IF, Wiley JS. Pruritus and severe iron deficiency in polycythaemia vera. Br Med J (Clin Res Ed). 1982;285:91-92.
310. Rector WG Jr, Fortuin NJ, Conley CL. Non-hematologic effects of chronic iron deficiency: a study of patients with polycythemia vera treated solely with venesections. Medicine (Baltimore). 1982;61:382-389.
311. Dallman PR, Beutler E, Finch CA. Effects of iron deficiency exclusive of anaemia. Br J Haematol. 1978;40:179-184.
312. de Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythaemia vera [letter]. Lancet. 1991;337:241.
313. Foa P, Massaro P, Caldiera S, et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur J Haematol. 1998;60:273-277.
314. Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol. 1995;89:313-318.
315. Swerlick RA. Photochemotherapy treatment of pruritus associated with polycythemia vera [letter]. J Am Acad Dermatol. 1985; 13:675-677.
316. Menage HD, Norris PG, Hawk JL, Graves MW. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. Br J Dermatol. 1993; 129:163-165.
317. Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Ann Hematol. 1996;73:91-93.
318. Chanarin I, Szur L. Relief of intractable pruritis in polycythaemia rubra vera with cholestyramine [letter]. Br J Haematol. 1975;29: 669-670.
319. Schramek A, Better OS, Adler O, et al. Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants. Lancet. 1975;1:70-71.
320. Salahudeen AK. Renal artery stenosis, erythrocytosis and renal artery occlusion [letter]. Nephrol Dial Transplant. 1987;2:53-54.
321. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc. 1995;43:899-901.
322. Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy [letter]. Br J Haematol. 2000;110:237-238.
323. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996; 28:768-772.
324. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation. 1993;87:1954-1959.
325. Thorne SA. Management of polycythaemia in adults with cyanotic congenital heart disease [editorial]. Heart. 1998;79:315-316.
326. Winslow RM, Butler WM, Kark JA, Klein HG, Moo-Penn W. The effect of bloodletting on exercise performance in a subject with a high-affinity hemoglobin variant. Blood. 1983;62:1159-1164.
327. Oldershaw PJ, Sutton MG. Haemodynamic effects of haematocrit reduction in patients with polycythaemia secondary to cyanotic congenital heart disease. Br Heart J. 1980;44:584-588.
328. Rosenthal A, Nathan DG, Marty AT, Button LN, Miettinen OS, Nadas AS. Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease. Circulation. 1970;42:297-308.
329. Chetty KG, Light RW, Stansbury DW, Milne N. Exercise performance of polycythemic chronic obstructive pulmonary disease patients: effect of phlebotomies. Chest. 1990;98:1073-1077.
330. Chetty KG, Brown SE, Light RW. Improved exercise tolerance of the polycythemic lung patient following phlebotomy. Am J Med. 1983;74:415-420.
331. Milne N, Light RW, Chetty KG. Exercise-induced changes in left ventricular function after phlebotomy in patients with polycythemic COPD. J Thorac Imaging. 1990;5:68-72.
332. Patakas DA, Christaki PI, Louridas GE, Sproule BJ. Control of breathing in patients with chronic obstructive lung diseases and secondary polycythemia after venesection. Respiration. 1986;49: 257-262.
333. Erickson AD, Golden WA, Claunch BC, Donat WE, Kaemmerlen JT. Acute effects of phlebotomy on right ventricular size and performance in polycythemic patients with chronic obstructive pulmonary disease. Am J Cardiol. 1983;52:163-166.
334. Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation. 2001;72:542-544.
335. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100:2310-2314.
336. Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol. 2001;12:1958-1964.
337. Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis [letter]. Ann Intern Med. 2001;134: 426-427.
338. Oren R, Beeri M, Hubert A, Kramer MR, Matzner Y. Effect of theophylline on erythrocytosis in chronic obstructive pulmonary disease. Arch Intern Med. 1997;157:1474-1478.
339. Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990;323:86-90.
340. Tefferi A, Bolander ME, Ansell SM, Wieben ED, Spelsberg TC. Primer on medical genomics, part III: microarray experiments and data analysis. Mayo Clin Proc. 2002;77:927-940.